Clinical Trials Logo

Cancer clinical trials

View clinical trials related to Cancer.

Filter by:
  • Suspended  
  • Page 1 ·  Next »

NCT ID: NCT06160700 Suspended - Cancer Clinical Trials

Serial Testing To Assess Cognitive Function In Cancer

Start date: April 20, 2022
Phase:
Study type: Observational

The purpose of this study is to examine the effects of immunotherapy on cognitive function of cancer patients and follow them clinically over a period of six months with the Montreal cognitive assessment (MoCA) to assess changes in cognition.

NCT ID: NCT05708924 Suspended - Cancer Clinical Trials

MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Start date: April 28, 2023
Phase: Phase 1
Study type: Interventional

To determine the maximum tolerated dose (MTD) of FT538 monotherapy when administered via intraperitoneal (IP) catheter and in combination with intravenous (IV) enoblituzumab in patients with recurrent ovarian, fallopian tube, and primary peritoneal cancer.

NCT ID: NCT05601206 Suspended - Depression Clinical Trials

Collaborative Care Intervention for Cancer Patients and Their Family Caregivers -LITE

CARES-Lite
Start date: November 14, 2023
Phase: N/A
Study type: Interventional

To test the efficacy of a web-based stepped collaborative care intervention to reduce symptoms of depression, pain, and fatigue and improve health-related quality of life (HRQL) in advanced cancer patients and to reduce stress and depression, and fewer CVD risk factors in caregivers.

NCT ID: NCT05124405 Suspended - Cancer Clinical Trials

Monitoring Your Exercise-related Metrics Over Time Via Wearable Electronic Devices

Start date: May 24, 2018
Phase: N/A
Study type: Interventional

To test the use of a continuous activity and heart rate tracker (Fitbit) and continuous glucose monitor (CGM) in monitoring daily exercise-related activities.

NCT ID: NCT04270916 Suspended - Cancer Clinical Trials

Prevalence and Impact on QoL From Ototoxicity in Cancer Survivors

Start date: February 3, 2020
Phase:
Study type: Observational

This study will involve collaborating with oncologists in the post-chemotherapy follow-up appointments. The participants who wish to consent to this study will then answer 3 short questionnaires (THI, HHIA and SF-36) about hearing loss, tinnitus and quality of life. The audiologist or the researcher, under the supervision of an audiologist, will then perform a simple, non-invasive hearing test on the participant. Should the participant have a hearing loss, they will be advise to seek help from their General Practitioner.

NCT ID: NCT01604863 Suspended - Cancer Clinical Trials

A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies

Start date: June 2012
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to determine the maximally tolerated dose (MTD) of HGS1036 when used in combination with the standard chemotherapeutic regimens paclitaxel plus carboplatin, cisplatin plus etoposide, or docetaxel.

NCT ID: NCT01562626 Suspended - Cancer Clinical Trials

Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors

Start date: September 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to test the safety and efficacy of an investigational drug called APS001F when given with flucytosine (5-FC) for treatment of solid tumors. APS001F is a recombinant Bifidobacterium longum (a live bacteria normally found in the digestive tract) that has been modified to produce an enzyme, cytosine deaminase (CD). The patient will first receive an injection of APS001F followed by oral 5-FC. APS001F is expected to go to the site of the tumor(s) where the agent will produce CD enzyme. CD enzyme will convert the 5-FC into 5-fluorouracil (5-FU) which is a standard chemotherapy drug for several types of cancer. Additionally, some patients will also receive 10% maltose injection, a sugar that has been shown to enhance the growth and effectiveness of APS001F in animals. This is the first study where APS001F is being used in humans.

NCT ID: NCT01050725 Suspended - Cancer Clinical Trials

Pilot Study of Biomarkers for Radiation Therapy

Start date: November 2009
Phase: N/A
Study type: Observational

The purpose of this study is to determine whether specific assays of DNA damage repair proteins can be used in patients undergoing radiation therapy. The ultimate goal of this research is to develop clinically useful biomarkers from blood samples that could be used to customize radiation treatment for individuals, leading to reduced side effects and improved outcomes.

NCT ID: NCT00523094 Suspended - Cancer Clinical Trials

Vibration Response Imaging (VRI) in Patients That Are Candidates for Undergoing Pulmonary Operation Procedure

Start date: September 2007
Phase: N/A
Study type: Observational

The primary objective of this study is to estimate the accuracy of the pre-operative VRI quantitative results versus the gold standard pre-operative perfusion scan. The secondary objective is to assess the correlation of the predicted post-operative lung function with the observed post-operative lung function (forced expiratory volume in 1 second [FEV1] and diffusing capacity of the lung for carbon monoxide [DLCO]) in patients who underwent surgical resection.

NCT ID: NCT00499499 Suspended - Cancer Clinical Trials

A Dose Escalation Study of E7107 Administered Intravenously on Days 1 and 8 Every 21 Days to Patients With Solid Tumors

Start date: July 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate E7107 in patients with solid tumors. This is an open label, dose-escalation study of E7107. The maximum tolerated dose (MTD) of the single agent will be established by determining the occurrence of dose limiting toxicities during the first three weeks of therapy (Cycle 1). Patients in this study will be treated at multiple dose levels, starting at 0.6 mg/m^2. Patients will receive E7107 as a 30-minute intravenous infusion on Days 1 and 8 every 21 Days.